S R Costford1, S A Crawford, R Dent, R McPherson, M-E Harper. 1. Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.
Abstract
AIMS/HYPOTHESIS: Obesity is an important risk factor for the development of type 2 diabetes, but not all obese individuals develop this complication. The clinical signs of type 2 diabetes can often be reversed with weight loss; however, it is unknown whether the skeletal muscle oxidative stress associated with type 2 diabetes remains after weight loss. We hypothesised that chronic exposure to high glucose and insulin would re-elicit impaired metabolism in primary myotubes from patients with a history of type 2 diabetes. METHODS: Obese participants with or without type 2 diabetes completed a standardised weight loss protocol, following which all participants were euglycaemic and had similar indices of insulin sensitivity. Satellite cells were isolated from muscle biopsies and differentiated under low or high glucose and insulin conditions (HGI). RESULTS: Cells from participants with no history of type 2 diabetes showed robust increases in mitochondrial content, citrate synthase and cytochrome c oxidase activities when exposed to HGI. This increase in oxidative capacity was absent in cells from patients with a history of type 2 diabetes. High glucose and insulin caused increased oxidative damage in cells from the latter, despite higher superoxide dismutase expression. Cells from patients with a history of type 2 diabetes were unable to decrease mitochondrial membrane potential in response to HGI, potentially due to lower levels of uncoupling protein-3. CONCLUSIONS/ INTERPRETATION: This is the first report to note that primary myotubes from patients with a history of type 2 diabetes are unable to adapt to a hyperglycaemic-hyperinsulinaemic challenge. We have demonstrated that impaired mitochondrial biogenesis and an inability to manage oxidative stress define a muscle phenotype at risk of obesity-associated type 2 diabetes.
AIMS/HYPOTHESIS: Obesity is an important risk factor for the development of type 2 diabetes, but not all obese individuals develop this complication. The clinical signs of type 2 diabetes can often be reversed with weight loss; however, it is unknown whether the skeletal muscle oxidative stress associated with type 2 diabetes remains after weight loss. We hypothesised that chronic exposure to high glucose and insulin would re-elicit impaired metabolism in primary myotubes from patients with a history of type 2 diabetes. METHODS:Obeseparticipants with or without type 2 diabetes completed a standardised weight loss protocol, following which all participants were euglycaemic and had similar indices of insulin sensitivity. Satellite cells were isolated from muscle biopsies and differentiated under low or high glucose and insulin conditions (HGI). RESULTS: Cells from participants with no history of type 2 diabetes showed robust increases in mitochondrial content, citrate synthase and cytochrome c oxidase activities when exposed to HGI. This increase in oxidative capacity was absent in cells from patients with a history of type 2 diabetes. High glucose and insulin caused increased oxidative damage in cells from the latter, despite higher superoxide dismutase expression. Cells from patients with a history of type 2 diabetes were unable to decrease mitochondrial membrane potential in response to HGI, potentially due to lower levels of uncoupling protein-3. CONCLUSIONS/ INTERPRETATION: This is the first report to note that primary myotubes from patients with a history of type 2 diabetes are unable to adapt to a hyperglycaemic-hyperinsulinaemic challenge. We have demonstrated that impaired mitochondrial biogenesis and an inability to manage oxidative stress define a muscle phenotype at risk of obesity-associated type 2 diabetes.
Authors: Timothy R Koves; John R Ussher; Robert C Noland; Dorothy Slentz; Merrie Mosedale; Olga Ilkayeva; James Bain; Robert Stevens; Jason R B Dyck; Christopher B Newgard; Gary D Lopaschuk; Deborah M Muoio Journal: Cell Metab Date: 2008-01 Impact factor: 27.287
Authors: Karim S Echtay; Damien Roussel; Julie St-Pierre; Mika B Jekabsons; Susana Cadenas; Jeff A Stuart; James A Harper; Stephen J Roebuck; Alastair Morrison; Susan Pickering; John C Clapham; Martin D Brand Journal: Nature Date: 2002-01-03 Impact factor: 49.962
Authors: Frederico G S Toledo; Elizabeta V Menshikova; Vladimir B Ritov; Koichiro Azuma; Zofia Radikova; James DeLany; David E Kelley Journal: Diabetes Date: 2007-05-29 Impact factor: 9.461
Authors: Céline Aguer; Colin S McCoin; Trina A Knotts; A Brianne Thrush; Kikumi Ono-Moore; Ruth McPherson; Robert Dent; Daniel H Hwang; Sean H Adams; Mary-Ellen Harper Journal: FASEB J Date: 2014-10-23 Impact factor: 5.191
Authors: Celine Aguer; Marc Foretz; Louise Lantier; Sophie Hebrard; Benoit Viollet; Jacques Mercier; Magali Kitzmann Journal: PLoS One Date: 2011-12-16 Impact factor: 3.240
Authors: A B Thrush; G Antoun; M Nikpay; D A Patten; C DeVlugt; J-F Mauger; B L Beauchamp; P Lau; R Reshke; É Doucet; P Imbeault; R Boushel; D Gibbings; J Hager; A Valsesia; R S Slack; O Y Al-Dirbashi; R Dent; R McPherson; M-E Harper Journal: Int J Obes (Lond) Date: 2017-11-20 Impact factor: 5.095